Abstract 2192: Enhancing veterinary cancer drug development with innovative bioanalytical assays

Abstract The development of biologic drugs for veterinary health requires precise and reliable bioanalytical tools. To that end, we have developed several new assays, extending our industry-leading portfolio of human bioassays to emerging veterinary therapeutic targets. Featured here are cell-based reporter bioassays: Canine ADCC Reporter Bioassay and Canine PD-1/PD-L1 Blockade Bioassay. Additionally, we present two new Lumit Immunoassays for characterizing binding to the FcRn receptor: Canine FcRn Binding Immunoassay and Feline FcRn Binding Immunoassay. Utilizing luminescence detection, these assays offer sensitive and specific measurement of target interactions. Our assay development process involves rigorous testing for accuracy, precision, linearity, and specificity, adhering to ICH guidelines. The assays demonstrated high sensitivity and specificity, as well as robust performance in detecting and quantifying the potency of target molecules. Our cell-based bioassays are available in convenient thaw-and-use kit formats, allowing for easy adoption and highly reproducible results. These assays can be utilized from early development through lot release, supporting every stage of the drug development process. Promega’s advanced bioassays and immunoassays provide a comprehensive platform for the development and characterization of veterinary biologic drugs. These tools support the entire drug development pipeline, enhancing the efficacy and safety of veterinary therapeutics through high sensitivity, specificity, and reproducibility. Additionally, our Lumit Immunoassays significantly reduce assay time compared to traditional ELISAs, providing faster and more efficient workflows for the characterization of binding interactions to the FcRn receptor. Citation Format: Jun Wang, Ildiko Kasza, Denise Garvin, Trish Trish, Rod Flemming, Jeff Nelson, Ngan Lam, Marjeta Urh, Mei Cong, Jamison Grailer. Enhancing veterinary cancer drug development with innovative bioanalytical assays [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2192.